The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

At the close in Stockholm, the OMX Stockholm 30 lost 1.01%. The best performers of the session on the OMX Stockholm 30 were ...

Here are the 2025 dividend forecasts for FTSE giants Unilever, GSK, and AstraZeneca James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on ...

Fed delivered the widely expected 25 bps rate cut yesterday. A pause in rate cuts can't be ruled out in December. See my ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc and Novo Nordisk. The Motley Fool has a disclosure policy. Making the world smarter, happier, ...